STAMICIS (Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific)
Product name
STAMICIS
Date registered
Evaluation commenced
Decision date
Approval time
153 (175 working days)
Active ingredients
tetrakis(2-methoxyisobutylisonitrile) copper(1) tetrafluoroborate
Registration type
New generic medicine
Indication
- Technetium (99mTc) Sestamibi is indicated for use in conjunction with stress testing as an adjunct in the diagnosis of ischemic heart disease. In these patients additional information about ventricular function may be derived by using the first pass technique.
- Technetium (99mTc) Sestamibi is indicated as a second line diagnostic aid to assist in the evaluation of patients for whom mammography is inconclusive.